Physician profile
Ivonne Vicente
NPI 1790888022
$49,176.46
in general payments reported to CMS, 2019-2025
14 companies · $37K in 2025
The $37K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,924 · 2020: $919 · 2021: $2,109 · 2022: $2,060 · 2023: $2,439 · 2024: $2,928 · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Food and Beverage: $7,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,750.00 |
| Food and Beverage | $7,415.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $42,919.31 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $2,266.72 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Novartis Pharmaceuticals Corporation | $1,968.50 | 2019-2025 | |
| Genzyme Corporation | $694.73 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $307.04 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $267.33 | 2019-2024 | Ultomiris |
| Genentech, INC. | $157.90 | 2020 | |
| Tg Therapeutics, INC. | $155.55 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $144.27 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $135.29 | 2019 | |
| Genentech USA, INC. | $58.45 | 2022-2025 | Ocrevus |
| Banner Life Sciences, LLC | $42.09 | 2021 | |
| Lundbeck LLC | $34.67 | 2020-2021 | |
| Allergan, INC. | $24.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivonne Vicente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.